Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...

Heart Failure IV: Classification and Diagnostic Evaluation

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...

Pulmonary Tuberculosis III

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:

Pulmonary Embolism I: Introduction

Pulmonary Embolism I: Introduction

Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

National Consortium on Pulmonary Vascular Disease Fellowship Training Summary.

Chest·2024

Same author

Amyloid cardiomyopathy in a large integrated health care system.

American heart journal·2019

Same author

Performance of the REVEAL model in WHO Group 2 to 5 pulmonary hypertension: application beyond pulmonary arterial hypertension.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2012

Same author

Validation of the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) pulmonary hypertension prediction model in a unique population and utility in the prediction of long-term survival.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2012

Same author

Anesthesia and pulmonary hypertension.

Progress in cardiovascular diseases·2012

Same author

World Health Organization Pulmonary Hypertension group 2: pulmonary hypertension due to left heart disease in the adult--a summary statement from the Pulmonary Hypertension Council of the International Society for Heart and Lung Transplantation.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2012

Search research articles

Related Experiment Video

Updated: May 20, 2026

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

Classification of pulmonary hypertension.

Dana McGlothlin¹

¹Division of Cardiology, UCSF Medical Center, University of California-San Francisco, 505 Parnassus Avenue, San Francisco, CA 94143-0124, USA. mcglothl@medicine.ucsf.edu

Heart Failure Clinics

|July 4, 2012

Summary

Pulmonary hypertension (PH) is linked to various conditions and reduces survival. Accurate diagnosis and treatment depend on understanding the specific cause and severity of PH.

Area of Science:

Cardiology
Pulmonology
Pathophysiology

Background:

Pulmonary hypertension (PH) is a serious condition associated with numerous diseases and risk factors.
The presence of PH significantly impacts patient survival and prognosis.
Effective management strategies are contingent upon identifying the underlying etiology and disease severity.

Purpose of the Study:

To outline the importance of classifying pulmonary hypertension (PH) based on etiology and severity.
To emphasize the role of combined clinical and hemodynamic assessments in diagnosing PH.
To highlight the evolving nature of PH classification and treatment as understanding of its mechanisms advances.

Main Methods:

Review of current clinical and hemodynamic classification systems for PH.

More Related Videos

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat

Published on: November 18, 2018

Induction and Characterization of Pulmonary Hypertension in Mice using the Hypoxia/SU5416 Model

Induction and Characterization of Pulmonary Hypertension in Mice using the Hypoxia/SU5416 Model

Published on: June 3, 2020

Related Experiment Videos

Last Updated: May 20, 2026

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Increasing Pulmonary Artery Pulsatile Flow Improves Hypoxic Pulmonary Hypertension in Piglets

Published on: May 11, 2015

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat

Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat

Published on: November 18, 2018

Induction and Characterization of Pulmonary Hypertension in Mice using the Hypoxia/SU5416 Model

Induction and Characterization of Pulmonary Hypertension in Mice using the Hypoxia/SU5416 Model

Published on: June 3, 2020

Integration of etiological factors and disease severity in diagnostic frameworks.

Analysis of the relationship between pathophysiological mechanisms and clinical presentation.

Main Results:

Classification of PH requires a multifaceted approach, integrating clinical findings with hemodynamic data.
Accurate etiological diagnosis is crucial for tailoring therapeutic interventions.
The current understanding of PH pathophysiology necessitates an adaptive classification system.

Conclusions:

A combined clinical and hemodynamic classification framework is essential for comprehensive PH diagnosis and management.
Evolving knowledge of PH's underlying mechanisms will continue to refine its classification and treatment paradigms.
Personalized therapeutic strategies informed by precise PH diagnosis are key to improving patient outcomes.